8-K filing — AYTU BIOPHARMA, INC (AYTU)
Filed: 2026-06-25 AccNo: 0001437749-26-021707 Size: 181 KB Item 1.02: Termination of a Material Definitive Agreement
Stocks · News reference
Aytu BioPharma And And Lannett Terminate Metadate Agreement Effective June 23, 2026; Co. To Continue Selling Existing Metadate Inventory And Pay Royalties Until Sales Cease
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14 to $14.5.